Earnings Call: Q3 2022

Nov 8, 2022

Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Stevanato Group third quarter 2022 financial results conference call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead, madam. Good morning, and thank you for joining us. With me today is Franco Stevanato, Executive Chairman, Franco Moro, Chief Executive Officer, and Marco Dal Lago, Chief Financial Officer. A presentation illustrating today's results can be found on the IR section of our website. As a reminder, some statements being made today will be forward-looking in nature. Such statements are only predictions. Actual events and results may differ materially as a result of risks we face, including those discussed in Item 3.D, entitled Risk Factors, in the company's annual report on Form 20-F for the fiscal year ended December 31, 2021, and filed with the Securities and Exchange Commission. We encourage you to review the information contained in our earnings release in conjunction with our SEC filings and our latest Form 20-F. The company does not assume any obligation to revise or update these forward-looking statements to reflect subsequent events or circumstances except as required by law. Today's presentation may contain non-GAAP financial information. Management uses this information in its internal analyses of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP financial measures, please see the company's most recent earnings press release. With that, I'll hand the call over to Franco Stevanato for opening remarks. Thank you, Lisa. As we come into the final month of 2022, we believe the fundamentals of our business remains strong, with favorable secular tailwinds in growing end markets. We are successfully executing against our long-term strategic and operational objectives. Industry demand trends remain healthy, and we expect this to continue as the global pipeline for new treatments in development hits record levels with approximately 60% tied to injectable delivery. We believe the bias towards injectable delivery format is boosted by favorable macro trends, such as the growth in biologics and biosimilars, the rise of chronic disease, pharmaceutical innovation, and self-administration of treatments. We believe our integrated end-to-end capability and robust portfolio of injectable products are ideally suited to match the scientific requirements of highly sensitive treatments such as GLP-1s. Today, we are a leader in diabetes treatment and maintaining a significant presence in the adoption of GLP-1s with business across both segments, demonstrating the value of an integrated offering. Thanks to the scientific and technological capability at our Technology Excellence Center, we are supporting customers in the early stage development of a new molecule and building a robust pipeline of promising opportunities. In this way, we accompany our customers alongside their pipeline with our unique and integrated value proposition. We are leveraging our proven expertise and leadership position in ready-to-use vials and cartridges to forge innovative products such as our next generation EZ-fill Smart platform. All in all, we believe we are well positioned to capitalize on the many opportunities ahead of us as we drive durable organic growth and create long-term shareholder value. I will now hand the call over to Franco. Thank you, Franco. On slide seven, for the third quarter of 2022, we delivered another solid quarter of double-digit revenue growth and achieved adjusted EBITDA margin of 26.8%. Revenue from high-value solutions grew 54% to EUR 74.4 million, representing 30% of total revenue in the third quarter of 2022. While we are pleased with our financial results, an increase in inflationary costs, particularly utility and logistics costs, tempered gross profit margin in the third quarter. Since that time, utility prices have started to come down from recent highs. Like everyone else, we are proactively managing the complexities around inflation and supply chains. We implemented efforts to mitigate the effects, and we believe we are successfully navigating the current environment. We remain optimistic on the demand landscape and our long-term growth trajectory. For the third quarter, new order intake totaled EUR 247 million. The year-over-year decrease was due to a significant drop in COVID-19 orders. Excluding COVID, new order intake increased by approximately 6% in the third quarter of 2022 compared to last year. Demonstrating that the underlying demand trends remain strong. At the end of the third quarter, our committed backlog increased 21% to just over EUR 1 billion. On slide 8, we recently announced the next evolution of our ready-to-use vial platform called EZ-fill Smart. Our R&D and continuous innovation allow us to further improve our ready-to-use platform. With our collaboration with Gerresheimer, we implemented several advancements. First, we increased automation in the manufacturing process to drive up productivity and reduce human error. The optimized platform features no glass to glass and no glass to metal contact, which improves the quality and integrity of the vials throughout the product lifecycle. Second, the teams redesigned the nest and tub configuration, which significantly reduces the risk of particle contamination during the fill and finish process. This is a substantial step up in quality, integrity, and performance. Third, we are introducing an alternative sterilization method that is more environmentally friendly compared to traditional ethylene oxide sterilization. This offers a path to improved sustainability. Together, all of these improvements are projected to further lower the total cost of ownership, increase quality, and shorten lead times for customers. Our EZ-fill platform is a well-established standard in the industrial process for ready-to-use drug containment solutions. This standardization ensures a seamless integration with the standard fill and finish operations and offers customers a secure and multi-source supply chain. Our efforts to drive continuous innovation are squarely in line with our long-term strategy of providing value-added integrated solution to our customers as we solidify our presence as a key partner to pharma and biotech. On page nine, we are making good progress in our priority projects in the U.S., Italy, and China. Our global capacity expansion plans are in response to growing demand for high-performance containment products to help ensure the integrity of highly sensitive treatments such as GLP-1s, monoclonal antibodies, and mRNA applications. We have already received a warm reception from customers who are pleased with the strategic investment in our EZ-fill technology, the improved proximity to pharma and CDMOs, and the commonality across our technology and quality standards worldwide. In the United States, construction on our new building in Indiana is well underway, and we still expect revenue generation to begin sometime in late 2023 to early 2024. In Italy, renovations are progressing in Latina and the new building in Piombino Dese is nearly complete. In the meantime, we are adding much needed EZ-fill capacity in our existing operations. In China, we started the preliminary work on the renovations of the facility while the design phase is still ongoing. We are focused on successfully executing on these projects and strengthening our regional organizational structures. The teams are doing an extraordinary job in supporting the evolving needs of customers amid favorable demand. On slide 10, I'm proud to announce that Stevanato and Bexson Biomedical were awarded the 2022 Partnership Innovation Award by the Parenteral Drug Association. This award recognized an innovative pain management therapy delivered through Stevanato on-body delivery system. We are working with Bexson to optimize the subcutaneous delivery of non-opioid pain management treatment that is specifically designed to help prevent misuse, to control dosing and extended delivery. It enables patients to manage their condition at home, which lowers cost and improves patient care. Our wearable device features a reusable cradle which minimizes the impact of electronic environmental waste. While this treatment is in pre-clinical stages, it is strategically important as the trend towards the self-administration of medicine evolves over the next decade. I now hand the call over to Marco. Thanks, Franco. Starting on slide 12, revenue for the third quarter of 2022 increased 14% to EUR 245.3 million over last year, driven by growth in the Biopharmaceutical and Diagnostic Solutions segment and favorable currency translation. On a constant currency basis, third quarter revenue grew 11%. As expected, contribution from COVID-19 accounted for approximately 13% of revenue, compared to approximately 16% for the same period last year. Gross profit margin in the third quarter of 2022 increased 210 basis points to 31.6%, principally driven by the strategic mix shift to more accretive high-value solutions, improved margin in engineering segment, and favorable currency translation. This was partially offset by higher inflationary costs, especially utilities and logistics. We recovered the majority of these costs through price adjustments, and we expect additional recoveries in future periods. There may be a delay in the timing of price adjustments, and we estimate that these unfavorably impacted gross profit margin by 1% in the third quarter. For the third quarter of 2022, operating profit margin was 19.4%. Excluding certain startup costs, adjusted operating profit margin improved to 20%, compared to 17% for the same period last year. This was driven by higher gross profit and an increase in other income, which included the residual fees from a previously disclosed contract modification. For the third quarter of 2022, this resulted in net profit of EUR 36.3 million or 14 cents of diluted earnings per share, adjusted net profit of EUR 37.7 million or adjusted diluted EPS of 14 cents, and adjusted EBITDA of EUR 65.8 million, which reflects an adjusted EBITDA margin of 26.8%. Please turn to slide 13 for segment results. The Biopharmaceutical and Diagnostic Solutions segment delivered another solid quarter of financial results. For the third quarter of 2022, revenue increased 20% to EUR 207.1 million compared to the same period last year, driven by strong growth in our core drug containment products as new capacity comes online. On a constant currency basis, the segment grew 15%. Revenue from high-value solutions increased 54% to EUR 74.4 million compared to last year. This represented 36% of segment revenue in the third quarter of 2022. Revenue from other containment delivery solutions increased 7% to EUR 132.7 million. For the third quarter of 2022, gross profit margin increased 150 basis points to 32.7% compared to last year, driven by favorable mix shift to high-value solutions and currency effects, which helped offset inflationary costs. Operating profit margin in the third quarter of 2022 increased to 22.8% compared to 18.1% for the same period last year. This improvement was driven by higher gross profit, lower G&A, and an increase in other income. Financial results for the engineering segment were as expected. For the third quarter of 2022, revenue decreased 9% to EUR 38.2 million compared to the same period last year, mostly due to timing and progression of projects in certain business lines. For the third quarter of 2022, gross profit margin increased to 21.5% compared to 15.4% last year, driven by an increase in mix of revenue for more accretive business lines and ongoing optimization efforts. As a result, operating profit margin in the third quarter of 2022 increased to 14% due to improved gross profit and lower G&A expenses. On slide 14, our balance sheet remains strong, and we believe we have ample liquidity to fund our investments in organic growth platforms. As of September 30, we had a positive net financial position of EUR 49.6 million and cash and cash equivalents of EUR 259.9 million. In the third quarter, capital expenditures were EUR 71.1 million as we continue to invest in our strategic global expansion plans. For the third quarter, net cash used for operating activities was EUR 3.8 million, mostly due to increase in working capital to support our strategic initiatives to drive sustainable growth and higher inventories to mitigate the supply chain risk in the current environment. One of the main reasons for negative free cash flow of EUR 46.3 million in the third quarter was cash used for investing activities of EUR 43.2 million. On page 15, we are increasing our 2022 guidance, mostly due to currency effects. Our updated guidance also considers that we are operating in a dynamic environment. We are backfilling our order book as revenue from COVID comes down. The mix shift to high-value solutions, action taken to accelerate efficiencies and initiatives to keep a tight rein on costs are helping to offset some of the inflationary impact. We are prudently managing the business and remain focused on our long-term growth objectives. As a result, we now expect revenues in the range of EUR 961 million-EUR 971 million, adjusted diluted EPS in the range of $0.52-$0.54, and adjusted EBITDA in the range of EUR 254.5 million-EUR 260 million. I will hand over the call back to Franco for closing comments. Thanks, Marco. In closing, we are executing the four pillars of our strategic and operational priorities to advance our global capacity expansion, grow the mix of high-value solutions, invest in R&D, and build a multi-year pipeline of new opportunities. We are excited about our future growth prospects and the ample opportunities in front of us. The rise in biologics and biosimilars, coupled with the macro trends of the aging population, the increasing incidence of chronic disease, and the shift towards the self-administration of medicines. Our customers are making groundbreaking strides in treatments to improve patient care. Supporting our customers in creating and delivering patient-centric solutions is central to our philosophy and vision. Our strategic priorities are designed to capitalize on these favorable trends, support customers, and exploit our full potential through our unique end-to-end capabilities. With that, let's open it up for questions. Thank you. This is the Chorus Call conference operator. We will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. To remove yourself from the question queue, please press star and two. Please pick up the receiver when asking questions. Anyone who has a question may press star and one at this time. The first question is from Patrick Donnelly with Citi. Please go ahead. Hi, good morning. This is Lizzie onto Patrick. Thank you so much for taking my question. I guess first for COVID, that puts me around 10% of revenues for the year. Just wondering if anything has changed there, and then I have one follow-up. Thanks. Hi, Lizzie, it's Lisa. I'm having a little bit of difficulty hearing you. I believe you asked if COVID was still expected to be 10% for the year, and then can you ask your second question again? Sure. For high-value solutions, can you just remind us on the trajectory there? Is it still supposed to be around mid-30s% a few years out as well, given that it was 30% of revenues for this quarter, just what you're seeing there as well. Thank you. Yes. Just to round up the questions, Marco will take it to give you the confirmation of COVID revenue for 2022, and we'll provide you the commentary on high-value solutions expectations for 2022 and the long-term trajectory. Thank you. Yeah, sure. Yeah. Thank you for the question. Thank you. Short answer is yes, we still expect 10% on revenue COVID on total revenues for the year. About our high-value solutions, we are pretty happy with the evolution. We have strong backlog in front of us for 2022, and we are now moving our guidance from 29%-30% about COVID revenues. We are still in a very good trajectory for high-value solutions. Yes, between 29%-30%. We are still pretty in line with our trajectory to reach mid-30% by 2026. Thank you. Thanks, Lizzie. Next question, please. The next question is from Derik De Bruin with Bank of America. Please go ahead. Hi. Good morning. Thank you for taking my questions. There's been a lot of confusion and I think people questioning because of some of the results from some of the other CDMOs in the space and some of the other component suppliers. Can you just talk about the demand for the underlying non-COVID related products? I mean, it looks like your backlog is increasing, but just some general commentary on what you're seeing in the market with demand continuing demand. Thank you, and I've got a follow-up. Yeah. Our view on the market is the demand is so strong, and the increase of order intake year-over-year due to the business is an evidence that the growth is consistent and continues to be in the direction also to pull the need of a high-value solution that we are putting on the market and are receiving a very warm welcome from our customers. We can understand that there is a slowdown linked to COVID, but we believe that is limited to that kind of business. We are now focused on the expansion of our capacity in Europe and in the U.S. to provide what our customer asking for, that is more high-value solution. We see this as a consistent trend in the short term and even in the longer run. Great. Just if you could offer some thoughts on what you think the COVID contribution could be to 2023 revenues. Your thoughts on what the overall FX impact will be on the top line for the fourth quarter, and any initial thoughts on 2022 so we can help triangulate our models. Thank you. For sure we probably will provide the guidance for 2023 in the next earnings call. The trend in revenue coming from COVID during the year has already started with COVID last quarter and this quarter. We still expect to be in line with our previous guidance for the year in terms of percentage. What I want to stress that is our capacity is not linked to COVID in any way because we are flexible. Also, our investment are linked to high-value solution mostly, if not 100%. This capacity is not dedicated to a single therapeutic area. We are providing what our customer need for many therapeutic areas in a very high promising business and therapeutic like mRNA application, like GLP-1. We are really engaged in the strong pipeline of our customer and focused on the execution of our CapEx for the next months. About the foreign exchange effect, we have in our model for 2022 about EUR 24 million tailwind related to foreign exchange effect. Thank you. That's what we have in our model based on Q4 expectations. Thank you very much. Welcome. Thanks, Jared. Next question, please. The next question is from Paul Knight with KeyBanc. Please go ahead. Hi, Franco. Can you talk to the Gerresheimer EZ-fill Smart collaboration? Will you both generate revenue independently? Will it be a joint venture? How should we think about the structure of that product and revenue recognition? Thank you, Paul, for the question. You may recall that, for the EZ-fill, what is the current EZ-fill, Gerresheimer's was one of the partner. We licensed our IP in the past, and it's still the agreement in place. Looking to the future, we decided to develop these technologies to transform a vial into Stelia together with Gerresheimer to combine our best expertise and value for our customers. This is the reason why we developed this intellectual property under the name of EZ-fill Smart. That is the next generation of the sterile configuration for vials and cartridges. In terms of the revenues, we will be independent, completely independent in terms of revenue for the sales of EZ-fill product. Obviously, in case we will license the new technology to third parties, we will share the license fee. In terms of the business, we will remain independent. The reason why we strengthen this cooperation is to push the adoption of the standard in the market and to give the right answer to the need of our customer to have multiple sources and best solution in terms of quality and performance. Franco, with 6% order growth, yet 21% increase in backlog, are you having some products you're having trouble meeting demand for? Is that what I would assume, or is it just product for later in the year? What's the dynamic behind the significant 21% backlog growth? Yes. Picking up the question, our backlog is growing. It's about EUR 1 billion. I can tell you we are pretty happy with the shifting to our high-value solutions that are representing an increasing share of our backlog. Okay. Thank you. Thanks, Paul. Next question, please. The next question is from David Windley with Jefferies. Please go ahead. Hi. Good morning, good afternoon. Thanks for taking my question. I'm curious first if you could talk to what specific products, if any, in your high-value solutions portfolio are seeing the most uptake. Relatedly, you've mentioned several times on the call GLP-1 specifically. Can we infer from that that you're spec-ed in on GLP-1s and participating in that growth arena in those commercial products? Yes. About the first part of your question, the portfolio of high-value solutions is growing rapidly, but without a specific driver because we are expanding our production, both syringes, vials, cartridges. We have some very good prospects for the future in terms of the conversion of the market to prefilled and cartridges. Maybe it will take a major part in the next year. Today we are representing our portfolio with a very good increase in all the business product line. In terms of therapeutic areas, I can confirm that we have a very well-balanced portfolio for different customers, different therapeutic areas, and different geography. You know, there are some trends that are very evident in the market today linked to some specific technologies like mRNA or therapeutic line like including GLP-1. We are engaged with the most important pharma companies, the big players in the market. We are in with the multiple projects with several customers. Okay. Franco, on the first question, I was hoping to get at things like, are you seeing Nexa and Alba uptake, you know, in terms of kind of the hierarchy of high-value solutions? Is that also something that you don't wanna talk about specifically, or would you be willing to talk about, you know, kind of some of those products that have the more significant IP wrapped around them? You know, our CapEx speaks for us because we are putting all our money in high-value solution. In terms of syringes, we are investing a lot in the new lines that are almost all dedicated to Nexa or other configuration. We are putting around in the new lines for this kind of product, and we believe that they can become one of the standard on the market in terms of syringes. In the meantime, we are also investing in refilled vial, not only for the technology to transform back into sterilized, but also because we believe that our container solution, the vials have some features, high quality, high mechanical resistance that are successful now and can be even more successful for the future. Got it. In terms of, the engineering business hasn't been touched on very much. You saw some decrease there. I'm wondering, to the extent that, you know, we've seen across the industry a number of manufacturers, including contract manufacturers, put a lot of capacity in place and spend a lot of CapEx themselves, was that a driver of, you know, engagement and activity for your engineering services business? Do we need to anticipate a, you know, essentially tough comps there or a lull following a lot of pull forward of capital expansion by manufacturers? Also in this case, I have to stress that we have a variety of solutions in our portfolio. That is, we are leaders in visual inspection, but we have a very strong technology also in assembly lines. Obviously in forming lines, which is our know-how from the very beginning of the company. There can be some fluctuation in each single product line, but overall, we continue to see very strong demand for innovation in these product lines. We mentioned several times artificial intelligence as a driver for our leadership position in visual inspection, but it's not the only option we have. Okay. Thank you for the answers. Thank you, David. Operator, next question, please. The next question is from Matt Larew with William Blair. Please go ahead. Hi, this is Madeline Mollman on for Matt Larew. Sort of piggybacking on the high-value solutions question. As COVID orders come down and they're replaced by non-COVID high-value solution orders, how do you see that impacting the margin dynamics? Is there a margin difference in terms of the products that are being ordered for COVID versus the non-COVID high-value solutions? Can you sort of speak to that a little bit and speak to how you see that impacting margins going forward? We mentioned in the past the fact that in COVID business we had about the same mix we had in other therapeutic areas. The percentage of high-value solution in COVID was similar with the overall company. Also we haven't experienced different margin in COVID compared to the other therapeutic areas. Even not sure, the short answer is no. On the other side, the good news is that we are replacing the COVID with other therapeutic area because we don't have any capacity constraint in doing that. We can see strong demand. As a matter of fact, we are executing our plan accordingly. Great. Thank you. Thank you. Eugene, the next question, please. The next question is from Tim Daly with Wells Fargo. Please go ahead. Great, thanks. Just wanted to dig a bit into the margin dynamics. BDS, a bit better than expected. Seems like you called out 100 basis points of price costs, timing lag. By contrast, engineering was better than expected. Seems like there's some low margin deliveries being delayed. How should we think about these normalizing into next quarter? Then on top of those kind of one-off factors, what was the energy impact to the margin? You know, if you think about it on a year-over-year delta. How are you thinking about energy impacts to margin in the fourth quarter in 2023? I think you had detailed that you've taken some actions around securing your energy sourcing. If you could dig, you know, provide more details there, that'd be really helpful. Yes, thanks for the question. In Q3, we estimate inflationary pressure hit our gross profit for about 1%. It means that we had about EUR 2.5-2.6 million we have been able to transfer to our customers in price increase. The main reason was the sharp increase in end of July into August and September of gas price in Europe. Excluding that, again, it would have been 1% more in gross profit margin. For the future, what we can see now is that the gas price in Europe went down in October and beginning of November. The tool we have in front of us in order to manage this is basically recalculating frequently our cost price accordingly with our customers. On top of it, obviously, we have many tools in place to minimize the impact through automation and cost efficiency. This is how we are managing the situation since some months ago, and this is how we will keep on going. All right. No, appreciate that detail. Then my second question, thinking about the capacity expansion plans specific to the Indiana facility. You know, seeing a lot of slacking in the construction markets in the US, you know, that would suggest that there's potential acceleration of timelines in terms of the, you know, doors opening, ribbon cutting, revenues getting recognized there faster than expected. If you are able to achieve better construction timelines, would there be any reason that you wouldn't be able to, I guess, achieve revenue recognition earlier there? Just from a, you know, whether it's licensing or anything like that. Thanks for the time. Appreciate it. Yeah, I have to confirm that we are on track with our plan. You know, the construction of the facility is an important piece, but also the delivery on the line is on track. That is very important. We are well satisfied about the action taken to prepare the crew, to prepare the staff that is already in Italy for training. In the meantime, we have also prepared the Italian staff to join the American one for the startup of the facility. I can confirm that we are in line with our plan, and we don't have any evidence of possible impact in the near term. All right. Thank you. Thank you. Next question, please. The next question comes from the line of John Sourbeer with UBS. Please go ahead. Hi. Thanks for taking the question. Yeah, first one here, just on pricing, given some of the inflationary costs, are you receiving any pushback from customers on pushing in price increases? Do you expect some of this pricing to, you know, flow through into, you know, continue to get price increases in 2023? Yeah. Good option to describe our approach to price increase because we passed on during this year cost to our customer. Looking at the overall picture of our relationship with customer, and we decide to have the approach for the long run and not for the immediate advantage. This approach made some dilutive effect in term of marginality because we passed cost without adding marginality on that. What I can anticipate that looking into the future we will be back to the normal practice to recalculate cost and having the normal marginality on that. It's something that is linked to our very intimate relationship with the customer, and we are progressing in that direction. Got it. I'm sorry if I missed in your prepared remarks, but I don't think I heard an update on when, the China expansion is expected to come online. Any change in the, timelines there? Thanks. As I anticipated in my comments, preliminary comments, we started some work in the facility for the rejuvenation of the facility. You know that is a brownfield, is not a greenfield. In the meantime, we are progressing with our design facilities. You know, we have a we several times say that we have a modular approach to the investment, so we are ready to adjust the rhythm of our investment to the actual need, actual demand. It's something that we look carefully everywhere, every time for each single project. Thanks for taking the question. remains unchanged. Got it. Thanks for the questions. Thanks, John. Eugenia, one more question, please. The next question is from Drew Ranieri with Morgan Stanley. Please go ahead. Hi, Franco and Marco. This is Jacob on for Drew. Thanks for taking the questions. I'll ask my two questions up front. I know you mentioned you won't be able to provide too much color, but thinking ahead to 2023, given the current environment, are you comfortable with consensus revenue at slightly over EUR 1 billion and EPS of $0.54? And then my second question, how are you thinking about the evolution of CapEx spend over full year 2022 and into the next couple years ahead? Thanks again for taking the questions. Today, the color we can provide is about our existing backlog. We are happy with the backlog we are building for 2022, first of all, but also for 2023. We have almost EUR 600 million for 2023, and also we are building the backlog for 2024. We are not providing guidance today about 2023, but also only talking about our backlog. Vittorio, call the second part of your question. Trend of CapEx. Okay. Trend of CapEx is, let's say we spent about EUR 202 million in the first three quarters. We now expect to have between EUR 300 million and EUR 330 million this year in 2022. As anticipated, we expect to be an important year for CapEx also 2023, as we completely build out the three facilities. Then we expect to enter into a more normalized phase starting from 2024. This is exactly what we expected before the IPO and the use of primary proceeds. Thanks, Drew. Next question, please. For any further questions, you may press star and one on your telephone. As a reminder, if you wish to register for a question, please press star and one on your telephone. Ms. Miles, gentlemen, there are no more questions registered at this time. Thank you, Eugenia. I just wanna say thank you to everyone for joining us today for the Stevanato Group third quarter 2022 earnings call, and we look forward to speaking with you in the future. Thank you very much. Ladies and gentlemen, thank you for joining. The conference is now over. You may disconnect your telephones.